###BASE_URL###

GENET-news

To stay informed you can subscribe to the GENET-news list.

 

2006-11-15 |

Gene therapy: Proceed with caution

In 1983, when only three genetic diseases could be detected effectively by screening tests and scientists knew very little about how genes were controlled, Technology Review argued that anticipated clinical trials of gene therapy would need to follow stringent guidelines, given the technology's previous failures. As Horace Freeland Judson explains in this issue (see "The Glimmering Promise of Gene Therapy"), not much has changed. Caught up in the promise of curing debilitating, life-shortening diseases by giving patients good copies of defective genes--and, it seems, eager for the glory of being the first to make gene therapy work in humans--some gene-therapy researchers have conducted sloppy, and even fatal, human trials in the intervening two decades.

Overview

News

2006-11-15 |

Gene therapy: Proceed with caution

In 1983, when only three genetic diseases could be detected effectively by screening tests and scientists knew very little about how genes were controlled, Technology Review argued that anticipated clinical trials of gene therapy would need to follow stringent guidelines, given the technology's previous failures. As Horace Freeland Judson explains in this issue (see "The Glimmering Promise of Gene Therapy"), not much has changed. Caught up in the promise of curing debilitating, life-shortening diseases by giving patients good copies of defective genes--and, it seems, eager for the glory of being the first to make gene therapy work in humans--some gene-therapy researchers have conducted sloppy, and even fatal, human trials in the intervening two decades.

Home: GENET

GENET-news & GENET-forum

GENET-news is providing a daily news service on a range of topics regarding genetic engineering. We are screening the worldwide English news, press releases and other publications to provide you with a strategic selection of information. GENET-news enables you to stay informed about all aspects of the global controversy around GE technologies and GE organisms. You can subscribe by  email.

The GENET-forum list provides you with additional background information and more voluminous reports. It is only open for GENET members. Please contact the  coordinator for membership and subscription.